Clinical OMICS

NOV-DEC 2017

Healthcare magazine for research scientists, labs, pathologists, hospitals, cancer centers, physicians and biopharma companies providing news articles, expert interviews and videos about molecular diagnostics in precision medicine

Issue link:

Contents of this Issue


Page 26 of 47 November/December 2017 Clinical OMICs 25 device won the $10 million Qualcomm Tricorder XPRIZE in 2017. "The diagnostic engine is an app on a phone or tablet," noted Basil Harris, the company's founder, CEO, and CMO. "The app is responsible for the fusion of data, requests for further inputs, the diagnosis, and suggested courses of action." It tells the user how and when to call upon the kits' peripheral devices, such as a blood pressure cuff, glucose sensor, a digital stethoscope, and urine tests. The device is based on analysis of actual patient data, artificial intel- ligence, and the founders' years of experience in clinical emergency medicine. The platform includes a set of non-invasive sen- sors that are designed to collect data on vital signs, body chemistry, and biological function. It also pulls together data from the patient's personal, clinical and family history. The first versions of DxtER, currently in early trails, will be able to continuously track blood glucose, white blood cell count, and hemoglobin, without any need to puncture the skin. The urine test will detect 10 substances and the digital stethoscope will help diagnose conditions such as pneumo- nia and COPD. Each component (e.g., the glucose sensor, digital stethoscope, and urine tests) will go through FDA-re- quired testing over the next few years. That's where POC is moving, toward more data analy- sis and flow, and products that even patients can use in their own home. For the near future, Glorikian sees a lot resting o n g o v e r n m e n t support. "It may come as a sur- prise to some, but the government is one of the biggest drivers of testing," Glorikian said. "If they continue to push for value-based reimbursement and POC testing yields better results more quickly, with better outcomes and lower costs, that's a model with tremendous value." Pathway's Nova sees particular growth in POC omics. "In a decade from now every physician's office will have a DNA reader of their own," he said. The patient, meanwhile, will be receiving all their healthcare data on their phone and bringing it with them to every visit. Two Pore Guys CEO Dan Heller (center) and team have raised more than $24 million to develop its handheld nanopore diagnostic tool (below).

Articles in this issue

Links on this page

Archives of this issue

view archives of Clinical OMICS - NOV-DEC 2017